EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy

Issei Saeki iD, Shigeo Shimose, Tetsu Tomonari, Takanori Ito, Joji Tani, Yasuto Takeuchi, Naoki Yoshioka, Takehito Naito, Mamiko Takeuchi, Satoru Kakizaki iD, Takeshi Hatanaka, Kyo Sasaki und 18 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0311084 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Issei Saeki und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, alpha-Fetoproteins, Prothrombin, Liver Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Durvalumab plus tremelimumab (Durva/Treme) combined immunotherapy is the first-line therapy recommended for unresectable hepatocellular carcinoma (HCC). Since sequential therapy is more effective in improving prognosis, tumor markers have been used as predictive biomarkers for response to systemic therapy. This study aimed to investigate the predictive ability of objective response (OR) by tumor markers for Durva/Treme therapy against HCC. In this multicenter study, 110 patients with HCC who received Durva/Treme therapy were retrospectively enrolled. The OR rate was 15.5%. To aid early decision-making regarding OR, we evaluated the predictors contributing to OR in two steps: before (first step) and 4 weeks after (second step) treatment induction. Changes in tumor markers (alpha-fetoprotein [AFP] and des-gamma-carboxy prothrombin [DCP]) from baseline to 4 weeks after treatment (ΔAFP/ΔDCP) were included as the input factors. In the first step, multivariable analysis identified only the baseline AFP level (odds ratio 3.497, p = 0.029) as a predictor of OR. Patients with AFP ≥ 400 ng/mL had a significantly higher OR rate than those with < 400 ng/mL (28.2 vs. 8.5%, p = 0.011), and there was no significant difference in progression-free survival (PFS) between the two groups. When AFP/DCP response was defined as a ≥10% reduction from baseline, multivariable analysis showed that AFP response (odds ratio 6.023, p = 0.042) and DCP response (odds ratio 11.657, p = 0.006) were both independent predictors of OR in the second step. The PFS of patients with AFP or DCP response was significantly longer than that of patients without AFP or DCP response. The study demonstrated that the use of AFP and DCP can predict the OR of patients with HCC receiving Durva/Treme therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Hepatocellularalpha-FetoproteinsProthrombinLiver NeoplasmsAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalProtein PrecursorsBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsAdultPrognosisTreatment OutcomeBiomarkers

Substanzen

alpha-FetoproteinsProthrombinacarboxyprothrombinAntibodies, Monoclonal, HumanizedtremelimumabAntibodies, MonoclonalProtein PrecursorsdurvalumabBiomarkers, TumorAFP protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Department of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School of Medicine, Tokushima, Japan.
  • Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Department of Gastroenterology and Neurology, Kagawa University, Faculty of Medicine, Kagawa, Japan.
  • Department of Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.

ORCID-Profile: Issei Saeki, Satoru Kakizaki, Motoyuki Otsuka, Hideki Kobara, Takahiro Yamasaki, Taro Takami

Zitieren

APA

Saeki, I., Shimose, S., Tomonari, T., Ito, T., Tani, J., Takeuchi, Y., Yoshioka, N., Naito, T., Takeuchi, M., Kakizaki, S., Hatanaka, T., Sasaki, K., Yasunaka, T., Sakata, M., Iwamoto, H., Itano, S., Shirono, T., Tanabe, N., Yamamoto, T., …, & Hepatology InVestigator Experts in Japan (HIVE-J) Study Group (2024). Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy. PLOS ONE. https://doi.org/10.1371/journal.pone.0311084

Vancouver

Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, et al. Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy. PLOS ONE. 2024. doi:10.1371/journal.pone.0311084

BibTeX
@article{Saeki2024,
  author = {Saeki, Issei and Shimose, Shigeo and Tomonari, Tetsu and Ito, Takanori and Tani, Joji and Takeuchi, Yasuto and Yoshioka, Naoki and Naito, Takehito and Takeuchi, Mamiko and Kakizaki, Satoru and Hatanaka, Takeshi and Sasaki, Kyo and Yasunaka, Tetsuya and Sakata, Masahiro and Iwamoto, Hideki and Itano, Satoshi and Shirono, Tomotake and Tanabe, Norikazu and Yamamoto, Takafumi and Kanayama, Yuki and Naganuma, Atsushi and Nishina, Sohji and Otsuka, Motoyuki and Kobara, Hideki and Kawashima, Hiroki and Takayama, Tetsuji and Kawaguchi, Takumi and Yamasaki, Takahiro and Takami, Taro and Hepatology InVestigator Experts in Japan (HIVE-J) Study Group, Hepatology InVestigator Experts in Japan (HIVE-J) Study Group},
  title = {Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0311084}
}
Kostenlos starten →